Close
RNS Number : 9216T
ValiRx PLC
23 July 2020
 

 

 

 

VALIRX PLC

("ValiRx", the "Company" or the "Group")

 

Result of AGM

 

ValiRx Plc (AIM: VAL) announces that at its Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.

 

The proxy votes are set out below:-

 

Resolutions

For

Against

Discretion

Resolution 1 - Receive the annual report and accounts

4,612,178

0

2,000

Resolution 2 - Re-appoint Gerry Desler as a director

4,226,311

377,739

2,000

Resolution 3 - Re-appoint Dr Suzanne Dilly as a director

4,579,542

23,437

2,000

Resolution 4 - Re-appoint Martin Lampshire as a director

4,579,542

24,623

2,000

Resolution 5 - Re-appoint Dr Kevin Cox as a director

4,580,958

23,207

2,000

Resolution 6 - Re-appoint the auditors

4,573,342

26,058

2,000

Resolution 7 - Set the auditors' remuneration

4,548,033

49,943

2,000

Resolution 8 - Provide authority to allot share capital

4,441,339

62,857

2,008

Resolution 9 - Provide authority to dis-apply statutory pre-emption rights (Special Resolution)

4,436,339

67,857

2,008

 

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

*** ENDS ***

 

For more information, please contact:

 

ValiRx plc

Tel: +44 (0) 20 7073 2628

www.valirx.com

Suzanne Dilly

Suzanne.Dilly@valirx.com

Cairn Financial Advisers LLP (Nominated Adviser)

Liam Murray / Jo Turner / Ludovico Lazzaretti

Tel: +44 (0) 20 7213 0880

Peterhouse Capital Limited (Sole Broker)

Duncan Vasey / Lucy Williams / Eran Zucker

Tel: +44 (0) 20 7469 0930

 

 

Notes for Editors

 

About ValiRx

 

ValiRx PLC accelerates the development of innovative medicines that enhance patient experience.  We do this by combining intellectual and financial resources to select, progress and partner a balanced portfolio of risk-reduced, early-stage technologies for translation into clinical candidates.

 

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGSEDFFDESSEIW